Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062133 | 0.87 | MTNR1A (0.55) | MTNR1AMTNR1BKDM4ELMNAPOLB | |
| SCHEMBL2062138 | 0.87 | MTNR1A (0.55) | MTNR1AMTNR1BKDM4ELMNAPOLB | |
| SCHEMBL11496541 | 0.79 | MTNR1A (0.72) | MTNR1AMTNR1BMAPTCA1CA2 | |
| SCHEMBL21715398 | 0.78 | MTNR1A (0.56) | MTNR1AMTNR1BKDM4ELMNAPOLB | |
| SCHEMBL11041746 | 0.73 | MTNR1A (0.64) | MTNR1AMTNR1BMAPTCA1CA2 | |
| SCHEMBL7658012 | 0.72 | MTNR1A (0.54) | MTNR1AMTNR1BKDM4ELMNAPOLB | |
| SCHEMBL6075910 | 0.72 | MTNR1A (0.50) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL3410798 | 0.72 | KDM4E (0.76) | KDM4ELMNAMAPTALDH1A1GLA | |
| SCHEMBL7021164 | 0.72 | MTNR1A (1.00) | MTNR1AMTNR1BMAPTCA1CA2 | |
| SCHEMBL9731034 | 0.72 | MTNR1A (1.00) | MTNR1AMTNR1BMAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | MTNR1A 2284/4885MTNR1B 1331/4885KDM4E 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.